Study the Effects of Vitamin D and Calcium Supplementation at Tolerable Upper Limit Doses on Calcium Metabolism.
NCT ID: NCT02019381
Last Updated: 2016-12-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
132 participants
INTERVENTIONAL
2013-09-30
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. To compare the two different intake guidelines for Calcium and Vitamin D Supplementation at its recommended tolerable upper limit on serum and urinary calcium in white postmenopausal Women.
2. Compare the effects above mentioned two intake guidelines on Vitamin D metabolism \[25(OH)D, 1,25(OH)2D\] and bone turnover.
Participants will be randomly assigned to Group A or Group B based on different dosages of study medications.
Group A: 10,000 IU (International Units)Vitamin D + Placebo (sugar pill) 600IU Vitamin D + Two pills Calcium containing 600mg calcium each.
Group B: 600 IU Vitamin D + Placebo (sugar pill) 10,000 IU Vitamin D
\+ Two pills Calcium containing 600mg calcium each.
In addition to the calcium supplements, they will guide to include approximately 800mg of calcium in their daily diet.
At visit 2, fasting blood and spot urine will be collected. A urinal will be dispensed for collection of 24-hour urine for urinary calcium to be brought in next day. Study medication will be dispensed and participants will be asked not to discard unused medications and to bring all study medications next study visit.
Visit 3, 4, 5, 6 will essentially be the same as visit 2, with subjects returning unused study medication and given new tablets each visit. Except on visit 6 no further study medications will be dispensed, after collecting the previous supply.
Food frequency questionnaires will be filled out at the initial visit and final visit. Diet will be assessed using 3-day diet history form and Nutrition Pro analysis software. Patients will be asked to refrain from taking other Vitamin D supplements and to continue their usual calcium intake.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Endocrine Society UL Dosage Vitamin D
Participants will be randomly assigned vitamin D + calcium dose based on Endocrine Society Upper limit guidelines. And given 10,000IU Vitamin D + 1200mg Calcium (600IU Placebo Vitamin D, in addition to two calcium tablets of 600mg) each to be taken per day.
Endocrine Society UL Dosage Vitamin D
Endocrine Upper limit arm will get 10,000IU Vitamin D and 1200mg Calcium
Calcium
1200mg of CaCO3 supplementation will be given to each participant in both groups
Institute of Medicine Dosage Vitamin D
Participants will be randomly assigned Vitamin D dose based on IOM guidelines; calcium dose will be as per IOM upper limits. And will receive 600 IU Vitamin D + 1,200 mg of calcium tablets to be taken per day.
Institute of Medicine Dosage Vitamin D
IOM arm will get 600 IU Vitamin D and 1,200 mg Calcium
Calcium
1200mg of CaCO3 supplementation will be given to each participant in both groups
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Endocrine Society UL Dosage Vitamin D
Endocrine Upper limit arm will get 10,000IU Vitamin D and 1200mg Calcium
Institute of Medicine Dosage Vitamin D
IOM arm will get 600 IU Vitamin D and 1,200 mg Calcium
Calcium
1200mg of CaCO3 supplementation will be given to each participant in both groups
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Willingness to discontinue self-administration of vitamin D and calcium supplements. Participants must be at least three months off supplements before starting the study.
3. Willingness to take study medications and participate in study for one year.
4. Written informed Consent Signed.
5. Patients with hypertension and diabetes stable for last three months.
Exclusion Criteria
2. Serum 25-hydroxyvitamin D level \>80 nmol/L or history of primary hyperparathyroidism.
3. Dietary calcium intake of \>2000mg/day will be excluded
4. Use of medication that influences bone or vitamin D metabolism (e.g. anticonvulsant medications, glucocorticoids, Highly Active AntiRetroviral Therapy \[AIDS treatment\], antirejection medications, chronic use of steroids, high dose diuretics)
5. Treatment with Hormone replacement therapy, Selective Estrogen Receptor Modulators, Calcitonin, Parathyroid hormone , androgens, bisphosphonates, phosphate or anabolic steroids 6 months prior to the study.
6. Use of systemic steroids (oral or intravenous) within the last year at an average dose of more than 5mg/day of oral prednisone or an equivalent for a period of three months or more prior to screening.
7. Chronic medical illness including Chronic liver disease, uncontrolled diabetes mellitus; recent history of myocardial infarction or heart failure; newly diagnosed or active malignancy; uncontrolled hypertension; obesity (BMI\>35 kg/m2); malabsorption, anemia, leukemia, or other hematologic abnormalities; lupus, rheumatoid arthritis, sarcoidosis, or other rheumatologic disease; chronic kidney disease, metabolic bone disease.
8. Unexplained weight loss of \>15% during the previous year or history of anorexia nervosa
9. \> 1 pack per day tobacco use or \> 2 alcoholic beverages per day
10. Unwillingness to forego self-administration of vitamin D and calcium-containing supplements.
11. Participation in another investigational trial in the past 30 days prior to the screening evaluation
12. Significant deviation from normal in medical history, physical examination, or laboratory tests as evaluated by the primary investigator.
13. Patients with unstable hypertension or diabetes.
50 Years
90 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Winthrop University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
John F. Aloia, MD
Chief Academic Officer, MD, Endocrinology.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Aloia, MD
Role: PRINCIPAL_INVESTIGATOR
Winthrop UH
Mageda Mikhail, MD
Role: STUDY_DIRECTOR
Winthrop UH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Winthrop University Hospital
Mineola, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Aloia JF, Katumuluwa S, Stolberg A, Usera G, Mikhail M, Hoofnagle AN, Islam S. Safety of calcium and vitamin D supplements, a randomized controlled trial. Clin Endocrinol (Oxf). 2018 Dec;89(6):742-749. doi: 10.1111/cen.13848. Epub 2018 Oct 1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13005
Identifier Type: -
Identifier Source: org_study_id